PMVP stock news · PMV Pharmaceuticals
Get alerts for PMVP
Follow PMV Pharmaceuticals (PMVP) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PMVPFree on the App Store and Google Play, or on the web.
PMV Pharmaceuticals shared new results from its Phase 2 trial for rezatapopt, showing strong responses in patients with advanced tumors.
Good for PMVPPMV reported a 48% confirmed response rate lasting a median 10.4 months among 65 ovarian cancer patients. The results support its planned 2027 application and strengthen the drug's outlook.
PMV Pharmaceuticals shared new results showing their drug rezatapopt works well for certain cancer patients.
Good for PMVPPMV Pharmaceuticals reported a 48% response rate among 65 ovarian cancer patients, with responses lasting a median 10.4 months. I read this as good news for PMVP.
PMV Pharmaceuticals is changing its leaders, with some directors leaving and new ones being chosen.
NeutralPMV filed a notice about officer or director changes and compensation arrangements, but gave no details. The filing does not change the outlook for PMV.